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Summary
Tumor-secreted extracellular vesicles (EVs) are critical mediators of intercellular communication 
between tumor cells and stromal cells in local and distant microenvironments. Accordingly, EVs 
play an essential role in both primary tumor growth and metastatic evolution. EVs orchestrate 
multiple systemic pathophysiological processes, such as coagulation, vascular leakiness, and 
reprogramming of stromal recipient cells to support pre-metastatic niche formation and subsequent 
metastasis. Clinically, EVs may be biomarkers and novel therapeutic targets for cancer 
progression, particularly for predicting and preventing future metastatic development.
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Introduction
Tumor-secreted EVs are emerging as critical messengers in tumor progression and 
metastasis. In this review we summarize the metastatic role of various EVs: microvesicles, 
exosomes, ectosomes, oncosomes, cytoplast etc (Colombo et al., 2014; Di Vizio et al., 2012; 
Headley et al., 2016; Thery et al., 2009; van der Pol et al., 2012). Exosomes are EVs 30-150 
nm in diameter derived from the multivesicular endosome pathway, but the term is used in 
many studies for small EVs recovered by various protocols which do not actually 
discriminate endosome-derived from plasma membrane-derived EVs. We will thus use the 
term as chosen by the authors of the articles described, not necessarily inferring an 
exclusively endosomal or plasma membrane origin of the EVs. EVs contain bioactive 
molecules, such as nucleic acids (DNA, mRNA, microRNA, and other non-coding RNAs), 
proteins (receptors, transcription factors, enzymes, extracellular matrix proteins), and lipids 
that can redirect the function of a recipient cell (Raposo and Stoorvogel, 2013). Cancer cell-
derived EVs promote angiogenesis and coagulation, modulate the immune system, and 
remodel surrounding parenchymal tissue, which together support tumor progression 
(Ciardiello et al., 2016; Peinado et al., 2011; Ratajczak et al., 2006; van der Pol et al., 2012). 
Clinically, circulating exosomes and microvesicles isolated from cancer patients have been 
associated with metastasis or relapse, and therefore could serve as important diagnostic and 
prognostic markers as well as therapeutic targets (Lener et al., 2015).
Physiological role of EVs: from development onwards
In 1967, Peter Wolf first demonstrated a role for platelet-secreted vesicles during blood 
coagulation (Wolf, 1967). In 1980, Trams et al. uncovered the essential role that EVs play in 
intercellular transport of trophic substances or nutrients (Trams et al., 1981). In 1983, two 
groups described the role of secretory vesicles in reticulocyte maturation through recycling 
of transferrin and its receptor (Harding et al., 1983; Johnstone et al., 1987; Pan and 
Johnstone, 1983). Pioneering studies by Raposo et al. demonstrated the importance of EVs 
derived from B cells in antigen presentation and T cell stimulation (Raposo et al., 1996). 
Since then, many studies have further demonstrated that EVs derived from professional 
antigen presenting cells, such as DCs, express class I, class II MHC, adhesion, and co-
stimulatory molecules that can directly activate CD4+ and CD8+ T cells (De Toro et al., 
2015; Zitvogel et al., 1998).
Pregnancy is characterized by an immune tolerant microenvironment in order to protect the 
fetus, and secretion of vesicles with immunosuppressant activities is increased in pregnant 
women as compared with non-pregnant ones. Several proteins, such as human ligands of the 
activating NK cell receptor NKG2D, FAS-ligand and TRAIL, secreted in placental EVs 
seem to be responsible for the generation of an immune-privileged microenvironment 
(Hedlund et al., 2009; Pap et al., 2008; Stenqvist et al., 2013). EV-mediated bidirectional 
communication between the embryo and uterine endometrium is critical for successful 
implantation of the embryo. Characterization of these EVs revealed several key mRNAs 
related to pluripotency, such as Oct4, Sox2, Klf4, c-Myc and Nanog (Saadeldin et al., 2014). 
Additionally, it has been shown that trophoblast cells shed EVs, and extracellular matrix 
metalloproteinase inducer (EMMPRIN) released in EVs may regulate angiogenesis, tissue 
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remodeling and growth of the placenta (Atay et al., 2011; Sidhu et al., 2004). Recent studies 
of EVs in Drosophila have also demonstrated that EVs may help establish the long range 
gradients of Wnt and Hedgehog required for proper anatomic axes and limb development 
(McGough & Vincent, 2016). To date, most of the studies published have been performed in 
vitro (Saadeldin et al., 2015), and more in vivo data are needed to understand the potential 
implications of EVs during embryonic development and how these EVs relate to the 
characterization and molecular pathways of tumor-derived EVs.
Role of EVs in promoting survival and growth of the primary tumor
During primary tumor formation, tumor cells require active communication with 
neighboring cells and their local microenvironment. During the last decade, the critical role 
of EVs in cell-cell communication between tumor cells and surrounding cells in the primary 
tumor microenvironment has been highlighted (Figure 1). EVs are thought to participate in 
multiple steps during invasive processes and perhaps contribute to early steps involved in 
metastasis.
Primary tumor subpopulations can share oncogenic molecules through EVs
Tumor-secreted vesicles can transfer oncogenic molecules between tumor cells within the 
primary tumor. Al-Nedawi et al. demonstrated that glioma cells expressing epidermal growth 
factor receptor variant III (EGFRvIII) secrete microvesicles harboring EGFRvIII and 
transfer it to EGFRvIII-negative cancer cells in the same primary tumor. This mutation is 
seen in 25-64% of patients with glioblastoma and despite not binding any known ligand, 
EGFRvIII signals constitutively at low levels (Gan et al., 2013). Upon EV-mediated uptake 
by recipient cells, EGFRvIII activates the mitogen-activated protein kinase (MAPK) and 
protein kinase B (PKB/Akt) signaling pathways, thereby inducing morphological 
transformation and accelerating cancer growth (Al-Nedawi et al., 2008).
Tumor-secreted EVs communicate with neighboring non-tumor cells
Tumor EVs exert complex effects on neighboring stromal cells such as endothelial cells and 
fibroblasts. Glioblastoma-derived microvesicles containing mRNA, miRNA, and angiogenic 
proteins are taken up by recipient cells and promote primary tumor growth as well as 
endothelial cell proliferation (Skog et al., 2008). Pancreatic cancer-derived exosomes 
expressing tetraspanin 8 recruit proteins and mRNA cargo that activate angiogenesis-related 
gene expression in endothelial cells (Nazarenko et al., 2010). Tumor-derived exosomes 
containing TGF-β convert fibroblasts into myofibroblasts, contributing to vascularization, 
tumor growth and local invasion (De Wever et al., 2008; Webber et al., 2010). Breast cancer-
derived exosomes also promote a myofibroblastic phenotype in adipose tissue-derived 
mesenchymal stem cells, resulting in increased expression of the tumor-promoting factors 
TGF-β, VEGF, SDF-1 and CCL5 (Cho et al., 2012).
Conversely, exosomes secreted by tumor stroma can also influence tumor progression. 
Breast cancer-associated fibroblasts (CAFs) secrete exosomes that have been shown to 
promote tumor motility, invasion, and dissemination of breast cancer cells through the Wnt-
planar cell polarity (Wnt-PCP) signaling pathway (Luga et al., 2012). Therefore, exosomes 
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mediate bi-directional communication between tumor cells and their environment and are 
central effectors of a feed-forward signaling loop that shapes the ever-evolving tumor 
microenvironment. However, the specific mechanisms through which healthy stromal cells 
are triggered to release exosomes that promote the malignant behavior of cancer cells remain 
to be determined.
In the past decade, much emphasis has been placed on the potential role of miRNAs 
packaged within EVs in regulating cell-cell interactions. Exosomes released by mast cells 
containing both mRNA and miRNA can be transferred to recipient cells and regulate gene 
expression (Valadi et al., 2007). Moreover, transfer of miRNAs specifically targeting PTEN 
expression from astrocyte-derived exosomes to invading tumor cells in the brain 
microenvironment promotes establishment of brain metastasis, although other autocrine and 
paracrine signaling may also cooperate during tumor progression (Zhang et al., 2015). 
However, the significance of this horizontal transfer of miRNAs for the global miRNA 
activity of a target cell remains unclear (Squadrito et al., 2014). Squadrito et al. detected 
transfer of miRNA activity via exosomes but the contribution to target gene repression was 
limited, suggesting exosomal miRNAs are degraded within recipient cell lysosomes 
(Squadrito et al., 2014). While these studies were performed in endothelial cells, other 
microenvironments, such as primary tumors, may facilitate increased miRNA transfer 
among cells (Baer et al., 2013). Recently, it was suggested that cancer exosomes, on average, 
contained only a single miRNA per exosome (Chevillet et al., 2014). However, 
stoichiometry of specific miRNAs may vary by tumor types and therefore the number and 
distribution of miRNAs secreted in other models may differ from these studies (Chevillet et 
al., 2014).
Interactions between metastatic cells and their microenvironment via miRNA-containing 
EVs have also been demonstrated (Zhang et al., 2015). Tumor-derived exosomes, but not 
those released by normal cells, contain key enzymes involved in miRNA biogenesis, which 
enabled cell-independent miRNA biogenesis within exosomes. Inhibition of target mRNA 
expression (e.g., PTEN and HOXD10) by transferred mature miRNAs can lead to cancer 
development in originally non-cancerous cells (Melo et al., 2014). Large oncosomes, 
atypically large EVs with diameter of 1-10 μM secreted by amoeboid tumor cells, from 
RWPE-2 prostate cancer cells are enriched in miR-1227 and may enhance the migration of 
fibroblasts (Morello et al., 2013). Similarly, comparing exosomes from prostate cancer stem 
cells with that of exosomes from the bulk tumor demonstrated a differential miRNA content 
that may contribute to local invasion and pre-metastatic niche formation through fibroblast 
migration (Sanchez et al., 2016). Highly abundant exosomal miRNAs, such as miR-100-5p, 
miR-21-5p and miR-139-5p, increased metalloproteinase (MMPs) −2, −9 and −13, RANKL 
expression and fibroblast migration upon transfection into prostate fibroblasts (Sanchez et 
al., 2016).
miRNAs within EVs from noncancerous cells within the tumor microenvironment have also 
demonstrated an ability to influence tumor growth and drug resistance. Metastatic breast 
cancer cells demonstrated a dormant phenotype when co-cultured with human bone marrow-
derived mesenchymal stem cells (BM-MSCs) secreting exosomes containing miR-23b. In 
recipient breast cancer cells, miR-23b decreased expression of MARCKS, a cell cycle and 
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motility regulator, suggesting that exosomal transfer of miRNAs from the bone marrow may 
promote tumor dormancy in a metastatic niche (Ono et al., 2014). Interestingly, exosomal 
miR-21 transfer from cancer-associated adipocytes and fibroblasts to ovarian cancer cells 
suppresses apoptosis and confers chemoresistance by binding to APAF1 (Au Yeung et al., 
2016). Most of the studies regarding the relevance of miRNA in cancer biology are 
performed in vitro, limiting our interpretation of the data. However, these numerous studies 
support an active role for shuttling of miRNAs between tumor cells and their 
microenvironment during tumor progression and metastasis.
Local tumor invasion is promoted by EV-mediated ECM remodeling
During cancer progression, the cellular and molecular milieu of stromal cells, and their 
extracellular proteins and enzymes are dynamically changing due to the evolving influence 
of tumor-derived EVs. Extracellular matrix (ECM)-remodeling is generally thought to 
promote the invasive phenotype of tumors. Secreted tumor exosomes carrying the ECM 
molecule fibronectin promote nascent adhesion assembly and increase cell motility (Sung et 
al., 2015). Proteomic analysis of tumor EVs revealed that annexins, α3 integrin, and 
ADAM10 were enriched in exosomes compared to ectosomes, and correlated with local 
invasion and cell migration, (Keerthikumar et al., 2015). Large oncosomes also harbor 
abundant bioactive molecules involved in local invasion (e.g., ARF6, Cav-1, 
metalloproteinases MMP9, and MMP2) and their abundance also correlated with tumor 
progression (Di Vizio et al., 2012). Sidhu et al. reported that microvesicles shed by tumor 
cells deliver EMMPRIN to fibroblasts, triggering the production of MMPs and enabling 
tumor invasion and metastasis (Sidhu et al., 2004). Endothelial cells stimulated by VEGF 
and FGF-2 release EVs containing MMPs that initiate the proteolysis necessary for tumor 
invasion and uninhibited angiogenesis (Taraboletti et al., 2002). Moreover, Hendrix et al. 
demonstrated that, Rab27b-mediated exocytic release of HSP90 exosomes from metastatic 
breast cancer cells activates MMP2, leading to degradation of ECM components, release of 
growth factors, and promotion of cancer cell invasion (Hendrix et al., 2010).
Association between hypoxic microenvironment and pro-angiogenic tumor-EVs
Among the factors that shape the primary tumor microenvironment, hypoxia plays a central 
role by promoting survival and propagation of tumor cells through modulation of the stroma 
(Finger and Giaccia, 2010). During hypoxia, breast cancer cells exhibit an increase in 
exosome release that may be regulated by hypoxia-inducible factor 1-α (HIF1-α) (King et 
al., 2012). Exosomes derived from highly malignant glioblastoma multiforme (GBM) cells 
growing in hypoxic conditions induce angiogenesis by stimulating cytokine and growth 
factor secretion by endothelial cells, thereby promoting pericyte migration (Kucharzewska et 
al., 2013). In addition, GBM patient-derived exosomes are enriched in multiple hypoxia-
regulated proteins involved in GBM pathogenesis. These observations suggest that the 
hypoxic microenvironment of the primary tumor may significantly impact exosome cargo 
and function, exerting local and systemic effects that warrant further investigation.
Tumor-secreted EVs may play a role in EMT
Tumor EVs also may participate in epithelial to mesenchymal transition (EMT). HRAS 
overexpression in Madin-Darby canine kidney epithelial cells promotes the packaging of 
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mesenchymal markers (e.g., vimentin and MMPs) in exosomes, potentially inducing EMT in 
recipient cells (Tauro et al., 2013). Although not functionally validated, there is an 
association between exosomes derived from mesenchymal cells and induction of EMT in 
epithelial cells (Tauro et al., 2013). Similarly, EVs isolated from the metastatic breast cancer 
cell line MDA-MB-231 stimulated with linoleic acid induce an EMT-like process in 
epithelial MCF10A cells (Galindo-Hernandez et al., 2014). Elucidating the role of EVs in 
the regulation of cell polarity and the initiation of EMT in vivo requires intensive future 
investigation (Lakkaraju and Rodriguez-Boulan, 2008).
Tumor EVs path through the extracellular compartment
Tumor-shed EVs circulate and can be isolated from nearly all body fluids, including blood, 
saliva and urine (Boukouris and Mathivanan, 2015; Ciardiello et al., 2016). Accumulating 
evidence indicates that circulating EVs mediate the “reprogramming” of multiple cell types 
at distant sites and influence diverse processes, such as coagulation, the immune response, 
and the establishment of a pre-metastatic niche (PMN).
Sticky vesicles: Tumor EVs promote coagulation
It is generally accepted that development of metastasis correlates with the risk of thrombotic 
complications, a leading cause of mortality in cancer patients (Stein et al., 2006). 
Coagulation and platelet accumulation at cancer sites prevent recognition of cancer cells by 
the immune system and promote cancer cell migration and dissemination (Sierko and 
Wojtukiewicz, 2007). Microvesicles involved in coagulation can originate from platelets, 
inflammatory cells, and cancer cells (Rak, 2010). Elevated circulating levels of 
microvesicles containing tissue factor (TF) and other coagulation-promoting factors are 
observed in cancer patients and correlate with increased risk of thrombosis (Hron et al., 
2007; Rak, 2010; Tilley et al., 2008). In vivo, TF-containing EVs released by monocytes 
bind to activated platelets and promote the generation of arterial thrombi (Falati et al., 2003). 
Interestingly, KRAS and p53 mutational status correlates with increased levels of TF in 
vesicles secreted by human colorectal carcinoma cells (Yu et al., 2005). Likewise, pancreatic 
cancer cell-derived microvesicles containing active TF and PSGL-1 were shown to 
accumulate at sites of injury, decreasing bleeding upon injection into living mice (Thomas et 
al., 2009). Together, these data suggest that tumor-secreted EVs have a potential pro-
thrombotic effect (Thomas et al., 2009) and support the relevance of coagulation in cancer 
progression and metastasis (Yu et al., 2008).
Tumor EVs demonstrate a complex impact on the immune system
The involvement of EVs in immune regulation was first proposed in early studies showing 
that immune cell-derived exosomes carry major histocompatibility complex (MHC) class I, 
MHC class II, and T cell co-stimulatory molecules (Raposo et al., 1996; Zitvogel et al., 
1998). Since then, the role of EVs in immune regulation has been intensively studied and 
several mechanisms have been proposed for the release of exosomes carrying 
immunomodulatory molecules by various immune cells upon infection, which can influence 
primary and secondary immune responses (Admyre et al., 2007; Bhatnagar et al., 2007).
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In addition to EVs derived from lymphocytes (Raposo et al., 1996), macrophages (Bhatnagar 
et al., 2007) and DCs (Zitvogel et al., 1998), non-immune cell-derived EVs, such as those 
released by epithelial and tumor cells, also express MHC class I molecules and/or tumor 
antigens (e.g., Mart-1/MelanA) and can modulate immune responses (Wolfers et al., 2001). 
While tumor EVs appear to have mostly immunosuppressive effects that support tumor 
progression and metastasis, there is evidence of EVs promoting both pro-tumor and anti-
tumor immunity, suggesting that the relationship between tumor EVs and the immune 
system is complex and may be largely dependent on cell type and EV cargo. The immune 
modulatory activity imposed by tumor exosomes can either involve direct signaling to 
immune cells or transfer of tumor antigens to DCs for antigen presentation to T cells to 
induce primary cytotoxic immune responses (Zitvogel et al., 1998). Chen et al. showed that 
under conditions of heat shock, mouse B cell lymphomas release exosomes carrying 
immunogenic molecules such as MHCs, CD40, CD86, RANTES and IL-1b. These tumor 
exosomes, in turn, induce the maturation of DCs leading to the activation of CD4+ and CD8+ 
T cell responses against the tumor (Chen et al., 2006).
Based on recent findings, several mechanisms have been proposed by which tumor-derived 
EVs mediate immunosuppression essential to tumor progression. For instance, breakdown of 
the subscapular sinus macrophage barrier in lymph nodes by chemotherapy and 
immunotherapy allows melanoma EVs to interact with B lymphocytes and initiate tumor-
promoting humoral immunity (Pucci et al., 2016). The presence of Fas ligand or tumor 
necrosis factor–related apoptosis-inducing ligand (TRAIL) on tumor microvesicles induces 
apoptosis in Jurkat and CD8+ T cells (Abusamra et al., 2005; Kim et al., 2005). Similarly, 
tumor-secreted exosomes suppress the immunological activity of natural killer cells by 
inhibiting their proliferation and compromising their cytolytic activity (Liu et al., 2006).
Suppression of the immune system through an increase in myeloid-derived suppressor cells 
(MDSC) has been correlated with tumor progression and poor survival (Gabrilovich and 
Nagaraj, 2009). Although the mechanism by which tumor exosomes influence MDSC 
differentiation remains controversial, Chalmin et al. proposed that MDSC activation involves 
Hsp72 expressed on tumor exosomes that promotes the activation of signal transducer and 
activator of transcription 3 (STAT3) in a Toll-like receptor 2 (TLR2/MyD88)-dependent 
manner (Chalmin et al., 2010). Controversially, Xiang et al. proposed that only in vivo-
derived tumor exosomes can mediate TLR2-dependent expansion of MDSCs, whereas in 
vitro-derived tumor exosomes regulate MDSC differentiation independently of TLR2 
signaling (Xiang et al., 2010).
Local interactions between tumors and innate immune cells ultimately determine whether 
the cancer can be contained locally or escape and invade both local and distant sites (Benito-
Martin et al., 2015). Breast cancer cell-derived exosomes stimulate the activation of tumor-
associated macrophages (TAMs), resulting in NF-κB activation and secretion of pro-
inflammatory cytokines (Chow et al., 2014). Tumor EVs were shown to transfer miR-150 to 
TAMs and trigger key angiogenic factors, such as VEGF, leading to augmented 
tumorigenicity (Liu et al., 2013). Breast carcinoma cell-derived exosomes increased 
mobilization of neutrophils and tumor growth through an unclear mechanism (Bobrie et al., 
2012). On the other hand, inhibition of TGF-β leads to the recruitment of CD11b+/Ly6G+ 
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tumor-associated neutrophils (TAN) with potent cytotoxic effect on tumor cells (Fridlender 
et al., 2009). These data suggest the local interaction between tumor cells and the immune 
system is extremely dynamic and requires further investigation to understand the balance of 
pro-tumor and anti-tumor immune responses.
Tumor EV's promote vascular leakiness and facilitate circulating tumor cell arrival to 
distant sites
Vascular leakiness is considered a hallmark of PMN formation (Huang et al., 2009; Psaila 
and Lyden, 2009). Melanoma-secreted vesicles induce vascular leakiness, inflammation and 
recruitment of bone marrow progenitor cells through upregulation of factors such as S100a8, 
S100a9 and TNF-α (Peinado et al., 2012). Furthermore, human breast cancer-derived 
exosomes promote vascular leakiness in the lung by upregulating a subset of S100 proteins 
and activating Src kinase signaling (Hoshino et al., 2015). Metastatic breast cancer cells that 
secrete miR-105-containing exosomes cause the destruction of tight junction protein ZO1 in 
recipient endothelial cells thereby increasing vascular permeability and susceptibility for 
metastatic invasion (Zhou et al., 2014). Taken together these data suggest that tumor-
secreted exosomes first permeabilize vessels by delivering specific cargo to endothelial cells 
and then diffuse through this compromised barrier to fuse directly with parenchymal cells 
within PMNs favoring metastatic colonization. However, more work is required to determine 
the exact mechanism by which EVs influence the integrity of the endothelial barrier as well 
as the specificity of this targeting within vasculature of different organs.
Tumor EVs create new sites hospitable for tumor growth: The PMN
The PMN is defined by the development of an environment distant from the primary tumor 
that is suitable for the survival and outgrowth of incoming circulating tumor cells. The 
concept of the PMN has developed from an early observation made by Stephen Paget in 
1889 that different tumor types tend to metastasize to different organs, suggesting that the 
microenvironment plays a role in dictating metastatic invasion (Paget, 1989; Peinado et al., 
2011).
The role of tumor-secreted factors and EVs in PMN initiation and evolution has recently 
gained greater recognition. In 2009, Jung et al. found that the combined effects of soluble 
factors and exosomes derived from CD44 variant isoform (CD44v)-positive pancreatic 
cancer cells mediate the formation of a PMN within the lymph node and lung (Jung et al., 
2009). CD105-positive microvesicles released from human renal cancer stem cells promote 
angiogenesis and the formation of PMNs in the lungs through a defined a subset of pro-
angiogenic mRNAs and microRNAs (Grange et al., 2011). Tumor exosomal miR-494 and 
miR-542p were transferred to lymph node stromal cells and lung fibroblasts, leading to 
cadherin-17 down-regulation and matrix metalloproteinase up-regulation (MMP2, MMP3, 
and MMP14) (Rana et al., 2013). Recently, the alteration of glucose metabolism by transfer 
of mir-122 from breast cancer-derived microvesicles to stromal cells has been shown to play 
an important role in the preparation of the PMN (Fong et al., 2015). By preventing glucose 
uptake in stromal cells via miR-122-mediated inhibition of pyruvate kinase, breast cancer 
cells create a PMN with greater glucose availability for their own utilization (Fong et al., 
2015).
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TLR3 activation in lung epithelial cells by tumor-exosomal non-coding snRNA enhances 
expression of S100A8, A100A9, MMP9, Bv8 and fibronectin which, in turn, contributes to 
lung PMN formation (Liu et al., 2016). Upregulation of TLR3 promotes secretion of 
chemokines that mobilize neutrophils (CD45+CD11b+Ly6G+Ly6Cint cKit+ VEGFR1+), as 
well as macrophages (F4/80+) and monocytes (VEGFR1+Ly6G−Ly6C+) that further support 
PMN formation (Liu et al., 2016). Interestingly, tumor-secreted exosomes have their own 
protein “zip-codes”, namely specific integrin profiles, that address them to specific target 
organs, thus determining metastatic organotropism (Hoshino et al., 2015). Tumor exosomes 
deliver messages which upregulate pro-inflammatory S100 molecules in resident cells of 
target organs and induce molecular and cellular changes that promote PMN development 
(Hoshino et al., 2015). Imaging of tumor-secreted EVs in metastatic organs has indeed 
demonstrated that the interactions of EVs with target cells are highly dynamic in PMNs and 
support their role in eliciting phenotypic alterations within stromal cells at future sites of 
metastasis (Suetsugu et al., 2013; Zomer et al., 2015).
Recruitment of different cell types, such as fibroblasts, endothelial cells, macrophages and 
various populations of bone marrow-derived cells (BMDCs) to the PMN is promoted by 
tumor-secreted exosomes (Costa-Silva et al., 2015; Peinado et al., 2012). Exosomes secreted 
from pancreatic tumor cells execute the stepwise progression of PMN formation in the liver 
(Figure 2) (Costa-Silva et al., 2015). Specifically, Kupffer cells, the resident macrophages in 
the liver, are the primary cell type that is activated following uptake of exosomes derived 
from pancreatic cancer cells (Costa-Silva et al., 2015). Pancreatic tumor-derived exosomes 
loaded with macrophage inhibitory factor (MIF) promote TGF-β secretion in Kupffer cells, 
stimulating neighboring hepatic stellate cells to secrete fibronectin, ultimately leading to the 
recruitment of BMDCs which completes PMN formation (Costa-Silva et al., 2015). 
Melanoma-secreted exosomes foster PMN formation in lung via reprogramming of BMDCs 
leading to the recruitment and activation of cells in the lung (Peinado et al., 2012). 
Mechanistically, transfer of MET from melanoma exosomes to c-Kit+ Tie2+ bone marrow 
progenitor cells results in a pro-vasculogenic behavior (Peinado et al., 2012). More recently, 
exosome-secreted MET has been suggested to promote hepatocellular carcinoma 
progression promoting the mobilization of normal hepatocytes, which may facilitate the 
protrusive activity of HCC cells through liver parenchyma during tumor metastasis (He et 
al., 2015). Evidence has demonstrated that gastrointestinal stromal tumors (GIST) release 
exosomes containing the oncogenic protein tyrosine kinase KIT and triggers the conversion 
of progenitor smooth muscle cells to tumor-promoting cells that promote tumor invasion 
(Atay et al., 2014).
Melanoma-derived exosomes promote cancer cell recruitment, extracellular matrix 
deposition, and vascular proliferation in the lymph nodes (Hood et al., 2011). Several genes 
related to cell recruitment (Stabilin 1, Ephrin receptor β4 and αv integrin), extracellular 
matrix (Mapk14, uPA, Laminin 5, Col 18α1, G-α13) and vascular growth factors (TNF-α, 
TNF-αip2, VEGF-B, HIF-1α, Thbs1) were upregulated by tumor-secreted exosomes in 
lymph nodes (Hood et al., 2011). Exosomes isolated from highly metastatic colorectal 
cancer promote metastasis by recruiting CXCR4-expressing stromal cells, establishing of a 
favorable metastatic microenvironment and reinforcing metastasis of low metastatic models 
(Wang et al., 2015).
Becker et al. Page 9
Cancer Cell. Author manuscript; available in PMC 2017 December 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Overall, these data support the role of tumor-derived EVs in both early and late PMN 
formation, and likely suggests their essential contribution to metastatic niche development 
upon the arrival of tumor cells as well as to the progression from micrometastatic to 
macrometastatic disease.
Clinical Potential of EVs as Biomarkers and Therapeutics
EVs as Biomarkers
Circulating tumor-derived EVs have emerged as promising biomarkers to monitor cancer 
progression and as novel targets for future anticancer therapies. Although many unanswered 
questions and methodological challenges remain, this rapidly advancing field will ultimately 
provide important insights into the relevance of EVs in the clinical setting.
Finding proteins unique to tumor-derived EVs has been the subject of intense research. One 
such tumor-derived EV biomarker is the epithelial cell adhesion molecule (EpCAM) (Runz 
et al., 2007). EpCAM positive exosomes increase during ovarian cancer progression and are 
significantly higher in patients with ovarian cancer than in women with benign ovarian 
disease and healthy control subjects (Taylor and Gercel-Taylor, 2008). Exosomal integrins 
(as opposed to tumor-expressed integrins) could serve as biomarkers to predict the likelihood 
of cancer as well as metastatic propensity for specific organ sites (Hoshino et al., 2015). 
Specific exosomal integrin combinations seem to dictate organ-specific metastasis. For 
instance, α6β4 and α6β1 exosomal integrins are associated with lung metastasis, αvβ5 
exosomal integrin with liver metastasis, and αvβ3 exosomal integrin with brain metastasis 
models (Hoshino et al., 2015). Circulating exosomes from patients with Stage IV melanoma 
contain a protein signature consisting of the melanoma-specific protein tyrosinase-related 
protein-2 (TYRP2), very late antigen 4 (VLA-4), HSP70, and MET oncoprotein (Peinado et 
al., 2012). Furthermore, exosomes from plasma of melanoma patients are enriched in 
caveolin-1 compared to the healthy controls, rendering caveolin-1 positive exosomes as 
another potential melanoma biomarker (Logozzi et al., 2009). Serum-circulating exosomes 
from melanoma patients have been demonstrated to contain S100B and Melanoma 
Inhibitory Activity (MIA) (Alegre et al., 2016). High levels of exosomes carrying the 
melanoma marker Melan-A and characteristic miRNA signatures could be isolated from 
liver perfusates of patients with liver metastases from uveal melanoma (Eldh et al., 2014). 
Exosomal glypican-1 has also been proposed as a diagnostic and prognostic marker for 
pancreatic cancer disease (Melo et al., 2015). In patients with pancreatic ductal 
adenocarcinoma (PDAC), the quantity of the protein MIF within exosomes may serve as a 
prognostic marker for liver metastasis. Circulating exosomes from stage I PDAC patients 
who later developed liver metastasis exhibited enhanced levels of MIF compared to patients 
whose cancer did not progress and to healthy control subjects (Costa-Silva et al., 2015).
Exosomal genetic material also shows potential as a diagnostic marker of cancer and 
metastasis. Tumor specific mRNA isolated from microvesicles from serum and tissue of 
glioblastoma patients reflects the mutational status of EGFRvIII (Pelloski et al., 2007; Skog 
et al., 2008). Microvesicles also carry single-stranded DNA (ssDNA) that recapitulates 
genomic aberrations such as oncogene amplifications (i.e., c-Myc), in the primary tumor 
(Balaj et al., 2011). In the metastatic setting, a higher level of double-stranded DNA 
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(dsDNA) in exosomes was found in aggressive melanoma as compared to melanoma with 
low metastatic potential or non-metastatic melanoma (Thakur et al., 2014). Importantly, 
exosomal dsDNA reflects the oncogenic mutational status of the respective parental cancer 
cell (Kahlert et al., 2014; Melo et al., 2015; Thakur et al., 2014), highlighting the utility of 
exosomal dsDNA as valuable biomarker for the detection of oncogenic mutations in the 
clinical setting.
MiRNAs within circulating EVs have diagnostic and/or prognostic potential for many cancer 
types. In patient serum, exosomal miR-17-92a was correlated with increased colon cancer 
recurrence and exosomal miR-19a was associated with a poorer prognosis (Matsumura et al., 
2015). Serum exosomal levels of seven miRNAs were found significantly higher in primary 
colorectal cancer patients compared to healthy controls. These miRNA levels decreased after 
surgical resection of tumor, suggesting their potential tumor origin (Ogata-Kawata et al., 
2014). Several miRNAs are differentially expressed in circulating tumor exosomes from 
prostate cancer, compared to controls (Bryant et al., 2012; Li et al., 2016). Exosomal 
miR-141 and miR-375 have been associated with metastatic prostate cancer (Bryant et al., 
2012; Li et al., 2016). Another study associated higher levels of miR-1290 and miR-375 
within serum exosomes with decreased survival in patients with castration-resistant tumors 
(Huang et al., 2015). Exosomal miR-107 and miR-574-3p concentrations were higher in the 
urine of men with prostate cancer compared with controls, suggesting EV- miRNAs could 
serve as a biomarker in other fluids (Bryant et al., 2012). In melanoma, lower levels of 
miR-125b in serum circulating exosomes were observed in advanced melanoma (Alegre et 
al., 2014). When comparing exosomes from patients with metastatic sporadic melanoma to 
patients with familial melanoma patients or unaffected control subjects, miR-17, miR-19a, 
miR-21, miR-126, and miR-149 were found to be expressed at higher levels (Pfeffer et al., 
2015). Exosomal miR-21 has been correlated with esophageal cancer recurrence and distant 
metastasis (Liao et al., 2016). One of the hurdles faced by analyzing both EV and non-EV 
derived miRNAs is that they could originate from either tumor or non-tumor cells and 
therefore their origin is unknown. Thus, translational studies will be crucial to determine the 
clinical utility of miRNAs-containing EVs as tumor biomarkers.
EVs for Therapy: Novel Mode of Drug Delivery and New Drug Targets
The properties of cancer exosomes in modulating the immune system and transforming 
healthy cells toward a malignant phenotype illustrate the clinical potential of exosomes in 
immunotherapy, therapeutic targeting and drug delivery. Activation of anti-tumor specific T 
cell responses by DC exosomes has been proposed to play a key role in suppression of 
established tumor growth (Zitvogel et al., 1998). The strategy of loading DC-derived 
exosomes with MHC/tumor antigen has been used for phase I clinical trials in patients with 
advanced melanoma (MAGE-A3, melanoma-associated antigen) (Escudier et al., 2005) and 
non-small cell lung carcinomas (MAGE-A3, -A4, and –A10) (Morse et al., 2005). These two 
studies showed the feasibility of DC exosome production and a tolerable safety profile for 
DC exosome therapy. In a subsequent phase II clinical trial in patients with advanced non-
small cell lung carcinomas, interferon-γ-maturated DC exosome therapy failed to show a 
durable clinical response, but increased NK cell activity was observed in some patients with 
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low initial NKp30 expression, correlating with longer progression-free survival (Besse et al., 
2016).
EV biogenesis serves as a key strategy for EV targeting in cancer therapy (Azmi et al., 2013; 
Bobrie et al., 2012; Iero et al., 2008). Several Rab proteins have been shown to be involved 
in the selective packaging and production of exosomes in both normal cells and tumor cells 
(Ostrowski et al., 2010; Rak, 2010; Raposo and Stoorvogel, 2013). Rab27a knockdown in 
highly metastatic melanoma cells led to significant reduction in exosome production, 
primary tumor size, and metastasis (Peinado et al., 2012). Thus, determining the profile of 
Rab proteins responsible for exosome release in cancer cells may lead to unique therapeutic 
opportunities. In addition to targeting EV production, targeting their specific oncogenic 
cargo (i.e MIF, MET) and transmembrane integrins may result in reduced metastasis.
Recently, tumor microvesicles have been implicated in promoting resistance to 
chemotherapy. Transfer of miR-100, miR-222 and miR-30a miRNAs from the exosomes 
derived from adriamycin- and docetaxel-resistant MCF-7 breast cancer cells to drug 
sensitive MCF-7 cells increased the drug resistance of the previously sensitive cell line, 
although this requires further validation to rule out induction of miRNA expression in drug 
sensitive cells (Chen et al., 2014). Boelens and colleagues demonstrated that exosomal RNA 
from stromal cells can be transferred to breast cancer cells, activating NOTCH3 as well as 
STAT1-dependent antiviral signaling in these cancer cell resulting in the expansion of cancer 
cells resistant to chemotherapy and radiation (Boelens et al., 2014). In addition to transfer of 
chemoresistance-associated biomolecules to recipient cells, another mechanism associated 
with chemoresistance is EV-mediated expulsion/sequestration of chemotherapeutic agents 
from cancer cells. To this effect, enhanced release of exosomes has been associated with 
increased cisplatin resistance in melanoma (Federici et al., 2014) as well as ovarian 
carcinoma cells (Safaei et al., 2005).
Based on their surface protein composition, exosomes may be directed to specific tissues 
(Costa-Silva et al., 2015; Hoshino et al., 2015). These properties make them promising 
nanovehicles for the biodelivery of therapeutic RNAs, proteins, and other agents. In fact, an 
in vivo proof of principle study showed that neuron-targeted exosomes loaded with BACE1 
siRNAs significantly reduced BACE mRNA (60%) and protein (62%), specifically in 
neurons (Alvarez-Erviti et al., 2011). Similarly, exosomes loaded with artificial siRNA 
against MAPK were able to efficiently knockdown the MAPK1 gene upon their delivery into 
monocytes and lymphocytes in vitro (Wahlgren et al., 2012). A significant reduction of the 
RAD51 transcript was observed in human embryonic kidney 293 cells (HEK293) and 
HCT116 colon cancer cell lines upon their incubation with exosomes carrying siRNA 
against RAD51 by electroporation (Shtam et al., 2013). These examples of cargo 
manipulation suggest that exosomes may prove beneficial as drug delivery vehicles.
Future directions
Currently, there are few markers (i.e., TSG101, syntenin, and simultaneous expression of 
three tetraspanins [CD9, CD63 and CD81]) to distinguish exosomes from other EVs, such as 
microvesicles or apoptotic bodies (Kowal et al., 2016). Furthermore, no reliable methods are 
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available to characterize exosomes secreted by normal tissues. Most studies to date are based 
on heterogeneous populations of EVs which leaves open the question of whether different 
EV subpopulations play unique biological roles in cancer progression. Do these various 
sized particles have distinct tumor cell origins (i.e., tumor stem cells)? Do heterogeneous 
particles target specific cell types and help facilitate formation of the PMN and metastatic 
microenvironment through different yet complementary mechanisms?
Further analysis of molecules, such as integrins, that define EV subpopulations involved in 
exosome uptake in metastatic organs is needed. Tumor exosomes exert their systemic effects 
partly through transfer of exosome cargo, resulting in the ‘reprogramming’ of stromal cells, 
immune cells and BMDCs. Is the underlying mechanism of reprogramming a genetic or 
epigenetic process? Are the effects permanent or transient? Interestingly, multiple 
observations suggest that exosomes may lead to the transfer of complete phenotypic 
features, resulting in a phenocopy of the tumor (Balaj et al., 2011; Costa-Silva et al., 2015; 
Hoshino et al., 2015; Peinado et al., 2012; Zomer et al., 2015). Advances in biomedical 
engineering would advance our understanding of exosome biology by providing answers to 
questions related to categorization, nomenclature, and function of EVs.
Currently available studies are based on exosome injection or in vitro models, but it is 
essential to analyze the role of exosomes in vivo through the generation of genetic models in 
which exosome dynamics could be monitored over time. How is the rate of exosome 
secretion changing as the primary tumor grows? Are exosomes complementary or redundant 
to soluble factors? Recently, development of a biotinylated EV-Gaussia luciferase reporter 
enabled in vivo tracking of IV-administered EVs (Lai et al., 2014). Furthermore, in vivo 
imaging of fluorescent and bioluminescent EV membrane reporters revealed that both EV 
uptake and translation of EV-delivered mRNAs in cancer cells occurred at a rapid rate (Lai 
et al., 2015). Ridder et al. have developed a Cre-lox-based model of tracking EV-mediated 
RNA transfer from tumor to MDSCs in the tumor microenvironment in vivo and showed 
immunosuppressive phenotype and miRNA profiles in response to EV uptake (Ridder et al., 
2015). Strikingly, Van Rheenen et al. have developed an intravital model to visualize 
spontaneous exosome transfer where highly metastatic cell-derived exosomes were received 
by less metastatic tumor cells and distant stromal cells (Zomer et al., 2015). Pittet and 
colleagues have developed additional in vivo labeling models for tracking tumor exosome 
dissemination via lymphatics (Pucci et al., 2016). In vivo models will serve to confirm the 
multiple roles of tumor exosomes during the metastatic process and potentially identify 
novel functions of exosomes in tumor biology.
By transferring content from tumor cells to non-cancerous cells, tumor EVs potently 
influence recipient cell behavior and promote the development of an environment hospitable 
toward cancer growth, invasion, and metastasis. Decoding how cancer-derived EVs mediate 
inter-cellular communication and harnessing these mechanisms for diagnostic and 
therapeutic purposes holds great promise to further understand cancer's widely systemic 
effects on the body and to improve the standard of care for cancer patients.
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Figure 1. Role of tumor-derived EVs on the primary tumor microenvironment
Tumor EVs cause fibroblasts to differentiate into myofibroblasts, which release MMPs and 
lead to extracellular matrix remodeling. The breakdown of ECM leads to the release of 
growth factors embedded in the ECM and promotes invasion through parenchymal cells. 
Tumor EVs activate tumor-associated macrophages to secrete G-CSF, VEGF, IL-6, and 
TNFα, which together promote angiogenesis and create an inflammatory niche. Tumor EVs 
affect immune system homeostasis mostly by triggering immunosuppressive changes that 
protect the tumor. Tumor EVs activate and expand Tregs and MDSCs, which inhibit CD8+ T-
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cell mediated targeting of the tumor. Furthermore, tumor EVs have been shown to express 
FasL and TRAIL on their membrane and directly induce apoptosis of CD8+ T-cells. Tumor 
EVs increase neutrophil mobilization and to be associated with increased tumor progression. 
Natural killer cells, which play an important role in antitumor immunity, can be either 
activated or suppressed by tumor EVs, depending on the tumor model studied and the EV 
cargo. Dendritic cells can be activated by the tumor-derived antigens delivered via tumor 
EVs and enforce a CD8+-mediated anti-tumor response. As the tumor grows, it develops 
metabolic demands that outgrow its blood supply and thus becomes increasingly hypoxic. In 
response to low oxygen concentrations, the tumor secrets angiogenic factors and EVs that 
promote blood vessel recruitment. EVs derived from the primary tumor can stimulate 
epithelial cells to release factors involved in EMT that trigger the loss of tumor cell adhesion 
(Fibronectin and Vimentin), ECM remodeling, and angiogenesis (MMPs), which together 
promote the release of tumor cells into the circulation and their spread to distant sites.
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Figure 2. Tumor-derived EVs promote pre-metastatic niche formation and metastasis
EVs play a distinct role at multiple steps in PMN formation at distant sites of future 
metastasis. Depending on the cancer cell of origin, EVs can circulate through both blood and 
lymphatic vessels to reach their destination for PMN initiation. Through an unknown 
mechanism, tumor EVs can induce vascular leakiness and interact with the resident cells of 
distant organs. Depending on their membrane composition, such as specific exosomal 
integrin combinations (exosomal α6β4 and α6β1 integrins associated with lung metastasis / 
exosomal αvβ5 integrin with liver metastasis), EVs are targeted to particular resident cell 
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types within a particular organ. Upon their uptake by the recipient cells, EVs can induce the 
expression of several inflammatory mediators (e.g. S100 family proteins, TGFβ, IL-6, IL-8 
and TNFα), resulting in the activation and remodeling of stromal cells and the recruitment 
of BMDCs to the PMN, which are critical for tumor progression. In pancreatic cancer, 
migration inhibitory factor (MIF)-containing exosomes are taken up by Kupffer cells 
promoting TGFβ secretion. TGFβ, in turn, then induces fibronectin secretion by hepatic 
stellate cells. The increase in fibronectin ultimately leads to the recruitment of BMDC's, 
which are critical for establishment of the PMN. In melanoma, exosomes can educate 
BMDCs through the transfer of MET and help establish a PMN in the lung. Melanoma-
derived exosomes can also prepare lymph node PMN formation, by promoting recruitment 
of melanoma cells, extracellular matrix deposition, and vascular proliferation in the lymph 
nodes.
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